AU2017363147B2 - Isotopically modified components and therapeutic uses thereof - Google Patents

Isotopically modified components and therapeutic uses thereof Download PDF

Info

Publication number
AU2017363147B2
AU2017363147B2 AU2017363147A AU2017363147A AU2017363147B2 AU 2017363147 B2 AU2017363147 B2 AU 2017363147B2 AU 2017363147 A AU2017363147 A AU 2017363147A AU 2017363147 A AU2017363147 A AU 2017363147A AU 2017363147 B2 AU2017363147 B2 AU 2017363147B2
Authority
AU
Australia
Prior art keywords
fatty acid
polyunsaturated fatty
acid
compound
pufa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017363147A
Other languages
English (en)
Other versions
AU2017363147A1 (en
Inventor
Mikhail Sergeevich Shchepinov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biojiva LLC
Original Assignee
Biojiva LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biojiva LLC filed Critical Biojiva LLC
Publication of AU2017363147A1 publication Critical patent/AU2017363147A1/en
Assigned to RTMFP ENTERPRISES INC. reassignment RTMFP ENTERPRISES INC. Request for Assignment Assignors: RETROTOPE, INC.
Assigned to BIOJIVA LLC reassignment BIOJIVA LLC Amend patent request/document other than specification (104) Assignors: RTMFP ENTERPRISES INC.
Application granted granted Critical
Publication of AU2017363147B2 publication Critical patent/AU2017363147B2/en
Priority to AU2023282263A priority Critical patent/AU2023282263A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
AU2017363147A 2016-11-17 2017-11-16 Isotopically modified components and therapeutic uses thereof Active AU2017363147B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023282263A AU2023282263A1 (en) 2016-11-17 2023-12-14 Isotopically modified components and therapeutic uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423699P 2016-11-17 2016-11-17
US62/423,699 2016-11-17
PCT/US2017/062107 WO2018094116A1 (en) 2016-11-17 2017-11-16 Isotopically modified components and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023282263A Division AU2023282263A1 (en) 2016-11-17 2023-12-14 Isotopically modified components and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
AU2017363147A1 AU2017363147A1 (en) 2019-05-23
AU2017363147B2 true AU2017363147B2 (en) 2023-09-14

Family

ID=62145748

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017363147A Active AU2017363147B2 (en) 2016-11-17 2017-11-16 Isotopically modified components and therapeutic uses thereof
AU2023282263A Pending AU2023282263A1 (en) 2016-11-17 2023-12-14 Isotopically modified components and therapeutic uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023282263A Pending AU2023282263A1 (en) 2016-11-17 2023-12-14 Isotopically modified components and therapeutic uses thereof

Country Status (6)

Country Link
US (2) US11166930B2 (enExample)
JP (3) JP7132630B2 (enExample)
KR (1) KR102580606B1 (enExample)
CN (1) CN110167546A (enExample)
AU (2) AU2017363147B2 (enExample)
WO (1) WO2018094116A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3536317A1 (en) * 2009-10-30 2019-09-11 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
JP7132630B2 (ja) 2016-11-17 2022-09-07 レトロトップ、 インコーポレイテッド 同位体修飾成分及びその治療上の使用
AU2019255739A1 (en) * 2018-04-20 2020-11-12 Biojiva Llc Stabilized polyunsaturated compounds and uses thereof
CN109601803A (zh) * 2018-11-07 2019-04-12 江西颐迪科技有限公司 一种能消除老年人体味并有助健康的饮料及其制作方法
WO2020102596A1 (en) * 2018-11-15 2020-05-22 Retrotope, Inc. Deuterated compounds, compositions, and uses
CA3135402A1 (en) * 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
EP4103145A4 (en) * 2020-02-12 2024-07-03 Retrotope, Inc. DEUTERATED POLYUNSATURATED FATTY ACIDS OR THEIR ESTERS FOR COSMETIC APPLICATIONS
KR20220140808A (ko) * 2020-02-14 2022-10-18 레트로토프 인코포레이티드 타우병증의 치료 방법
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US11351143B1 (en) * 2021-02-05 2022-06-07 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170136A1 (en) * 2021-02-05 2022-08-11 Retrotope, Inc. Methods for assessing a patient's response to treatment of a neurodegenerative disease with deuterated arachidonic acid
EP4452244A4 (en) 2021-12-21 2026-02-18 Biojiva Llc ANTI-INFLAMMATORY METHODS INVOLVING SITE-SPECIFIC COMPOSITIONS COMPRISING ISOTOPICALLY MODIFIED FATTY ACIDS
WO2023158641A1 (en) * 2022-02-15 2023-08-24 Retrotope, Inc. Synergistic combination therapy for treating als
CN120435548A (zh) * 2022-12-01 2025-08-05 匹克生物酶高科技有限公司 用于解毒内源醛类的食品和药物组合物
KR20250110548A (ko) 2024-01-12 2025-07-21 현대모비스 주식회사 전기자동차용 배터리팩 케이스

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105609A1 (en) * 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
US20030069208A1 (en) 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US7635722B1 (en) * 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
US6544764B2 (en) * 2000-11-14 2003-04-08 Applera Corporation Isolated human dehydrogenase proteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US20050065099A1 (en) 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
PT1909600E (pt) * 2005-07-29 2012-07-24 Tima Foundation Composição para moderar o metabolismo do álcool e para reduzir o risco de doenças induzidas pelo álcool
JP2009508867A (ja) 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
JP5649454B2 (ja) 2008-01-08 2015-01-07 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体
KR20160121610A (ko) 2008-04-01 2016-10-19 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
WO2009137045A2 (en) * 2008-05-07 2009-11-12 The Board Of Trustees Of The Leland Stanford Junior University Crystal structure of aldehyde dehydrogenase and methods of use thereof
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
US20120005765A1 (en) * 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
US9259409B2 (en) * 2011-01-24 2016-02-16 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
AU2012249920B2 (en) * 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
CA2834274C (en) * 2011-04-26 2021-08-03 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
US10058522B2 (en) * 2011-04-26 2018-08-28 Retrotope, Inc. Oxidative retinal diseases
JP7132630B2 (ja) 2016-11-17 2022-09-07 レトロトップ、 インコーポレイテッド 同位体修飾成分及びその治療上の使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105609A1 (en) * 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives

Also Published As

Publication number Publication date
KR20190085973A (ko) 2019-07-19
JP2020500193A (ja) 2020-01-09
US20190282529A1 (en) 2019-09-19
US20220133668A1 (en) 2022-05-05
JP7132630B2 (ja) 2022-09-07
AU2023282263A1 (en) 2024-01-18
KR102580606B1 (ko) 2023-09-19
JP7464661B2 (ja) 2024-04-09
AU2017363147A1 (en) 2019-05-23
JP2024081733A (ja) 2024-06-18
US11166930B2 (en) 2021-11-09
WO2018094116A1 (en) 2018-05-24
CN110167546A (zh) 2019-08-23
JP2022166245A (ja) 2022-11-01

Similar Documents

Publication Publication Date Title
AU2017363147B2 (en) Isotopically modified components and therapeutic uses thereof
US20250325512A1 (en) Neurodegenerative Disorders And Muscle Diseases Implicating Pufas
US20220304968A1 (en) Oxidative retinal diseases
US10058612B2 (en) Impaired energy processing disorders and mitochondrial deficiency
AU2019204443B2 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
Liu et al. Role of long-chain and very-long-chain polyunsaturated fatty acids in macular degenerations and dystrophies
HK40011999A (en) Isotopically modified components and therapeutic uses thereof
JP7570108B2 (ja) ミトコンドリア病の治療における使用のためのカンナビジオールおよび／またはその誘導体
HK40035235A (en) Oxidative retinal diseases
HK1233443B (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
HK1195011B (en) Neurodegenerative disorders and muscle diseases implicating pufas
HK1195011A (en) Neurodegenerative disorders and muscle diseases implicating pufas
HK1195018B (en) Oxidative retinal diseases
HK1195018A (en) Oxidative retinal diseases

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RTMFP ENTERPRISES INC.

Free format text: FORMER APPLICANT(S): RETROTOPE, INC.

HB Alteration of name in register

Owner name: BIOJIVA LLC

Free format text: FORMER NAME(S): RTMFP ENTERPRISES INC.

FGA Letters patent sealed or granted (standard patent)